Cystic Fibrosis (CF) Program – Inhaled PB01
Cystic fibrosis is a rare, chronic, life threatening disease characterised by excessive mucus, inflammation and infection in the lungs which leads to loss of lung function and lung destruction. The median forecast survival age for a person with CF is approximately 40 years.
Despite the recent expansion in treatment options for CF with the introduction of medicines targeting specific CF mutations, namely Kalydeco™(ivacaftor) and Orkambi™(ivacaftor + lumacaftor), there still remains a significant need for medicines which target the underlying lung inflammation and resulting lung remodelling.
Paranta is developing an inhaled form of PB01 for the treatment of CF lung disease. PB01 targets lung inflammation, fibrosis and mucus production and therefore has the potential to slow the progression of lung disease and preserve lung function in people living with CF.